In accordance with the findings of Engelholm et al1, targeting Endo180 by genetic silencing or treatment with the neutralizing mAbs A5/158 and 39.10 can block the migratory behaviour of osteosarcoma and other invasive tumour cell types 6, 7 (Figure 1). The gene discussed is MRC2; the disease is osteosarcoma.